On September 11, 2020 Pacira BioSciences, Inc. (NASDAQ: PCRX) reported that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020 (Press release, Pacira Pharmaceuticals, SEP 11, 2020, View Source [SID1234565027]). Live audio of the virtual event can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2020 Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel coronavirus pandemic (commonly referred to as COVID-19) reported that Alan Joslyn, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference (the "Conference") (Press release, Oragenics, SEP 11, 2020, View Source [SID1234565026]). The Conference is to be held virtually on September 14–16, 2020, and Dr. Joslyn is scheduled to present on Wednesday, September 16, 2020 at 11:00 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Dr. Joslyn’s presentation will be available through H.C. Wainwright’s virtual conference portal, located here, and the presentation will be archived on the Oragenics website at View Source

In addition, Dr. Joslyn will be available for virtual one-on-one meetings from September 14–16, 2020. To schedule a meeting with Dr. Joslyn, please contact the Conference coordinator at [email protected].

On September 11, 2020 Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, reported that the company will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference in September (Press release, Ascendis Pharma, SEP 11, 2020, View Source [SID1234565025]). Company executives will provide a business overview and update on the company’s pipeline programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details

Event 18th Annual Morgan Stanley Virtual Global Healthcare Conference
Location Virtual
Date Thursday, September 17, 2020
Time 3:30 p.m. Eastern Time
A live webcast of the presentation will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the events for 30 days.

On September 11, 2020 Omeros Corporation (Nasdaq: OMER) reported that Gregory A. Demopulos, M.D., chairman and chief executive officer, reported that it will present at the Cantor Virtual Global Healthcare Conference next week (Press release, Omeros, SEP 11, 2020, View Source [SID1234565024]). The presentation is scheduled for Tuesday, September 15, 2020 at 11:20 a.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations section of the company’s website at www.omeros.com under "Events."

On September 11, 2020 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, reported that it will showcase recent progress in its clinical programs targeting Tau for neurodegenerative diseases at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference (Press release, AC Immune, SEP 11, 2020, View Source [SID1234565023]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AC Immune CEO Prof. Andrea Pfeifer, Ph.D., will discuss the Company’s comprehensive anti-Tau clinical pipeline, which leads the industry in addressing this important neurodegenerative pathology. The extent of Tau pathology correlates very strongly with clinical decline throughout the course of disease, and AC Immune’s three clinical-stage therapeutic assets – an antibody, a small molecule inhibitor, and a vaccine – collectively target the full spectrum of Tau pathology by inhibiting both early intracellular Tau aggregation and extracellular seeding and spreading of pathological Tau protein. Prof. Pfeifer will also discuss recently published results demonstrating the ability of its differentiated Tau positron emission tomography (PET) imaging agent PI-2620, which was discovered in a research collaboration with Life Molecular Imaging, to potentially facilitate an earlier and more reliable diagnosis of patients with progressive supranuclear palsy (PSP).

H.C. Wainwright 22nd Annual Global Investment Conference
Date: September 15, 2020 | 10:00–10:20 am ET / 4:00–4:20 pm CET
Format: Virtual Presentation followed by Q&A
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA

The presentation will be followed by a question and answer session. A webcast of the presentation and Q&A will be available on the Events Page of AC Immune’s website.